pravastatin – ABC CARDIOL

ABC

Artigo Original

The evaluation of short term effects of awareness programs and pravastatin therapy on subjects from private clinics at high risk for cardiovascular disease

Raul D. Santos et al. Luiz O. do Nascimento Raul C. Maranhão

PURPOSE: To evaluate short-term efficacy of awareness programs (AP) in reducing coronary heart disease risk factors (CHDRF). METHODS: High risk hypercholesterolemic patients were divided in 2 groups during 16 weeks. Group A (n=417, 54.3±10.0 years, 55% males) received verbal and written orientation on CHDRF control, and group B (n=180, 54.4±10.9 years, 45% males) received only verbal orientation. All participants received pravastatin 10mg q.d. for 12 weeks. The evolution of body weight, arterial pressure, lipid profile, Castelli’s I and II indexes (TC/HDL and LDL/HDL), and Framingham scores were evaluated. RESULTS: At baseline, A had a lower HDL-C (40.0±11.0 vs 43.0±11.0mg/dl, p=0.013) and a higher index I (8.2±3.0 vs 7.6±2.3, p=0.008) than B. After 16 weeks, A had greater change than B in TC (-28.0 vs -25.0, p<0.05), LDL-C (-29.0 vs -27.6, p<0.05), HDL-C levels (+13.7 vs +10.8, p<0.05) and in the Castelli's Index (-39.0 vs -33.0; p<0.05). In both groups pravastatin use potentialized the effects of diet on the lipid profile. CONCLUSION: The AP seemed to be more effective than verbal orientation alone in CHDRF reduction at short-term.

Read Full Article

The evaluation of short term effects of awareness programs and pravastatin therapy on subjects from private clinics at high risk for cardiovascular disease

Electronic Document Format (Vancouver)

Electronic Document Format (ABNT)

Electronic Document Format (APA)

Electronic Document Format (ISO)